Co-Authors
This is a "connection" page, showing publications co-authored by HAGOP M KANTARJIAN and TAREQ ABUASAB.
Connection Strength
0.586
-
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications. Am J Hematol. 2024 07; 99(7):1434-1436.
Score: 0.238
-
Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis. Leuk Res. 2024 Sep; 144:107563.
Score: 0.061
-
Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis. JCO Oncol Pract. 2024 Dec; 20(12):1637-1644.
Score: 0.061
-
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 2024 Apr; 11(4):e276-e286.
Score: 0.059
-
Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. Haematologica. 2024 01 01; 109(1):293-297.
Score: 0.058
-
Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 06; 98(6):E142-E144.
Score: 0.055
-
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol. 2023 03; 98(3):E53-E56.
Score: 0.054